Vaxxinity (VAXX) 10-Q 2023 Q2 Quarterly report

1

Exhibit 32.1

CERTIFICATIONS OF PRINCIPALEXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANTTO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Vaxxinity,Inc. (the “Company”) on Form 10-Q for the quarter ended

June 30, 2023, as filed with the Securities and Exchange Commission onthe date hereof (the “Report”), the undersigned

hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of

2002, that, to the best of their knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d)of the Securities Exchange Act

of 1934, as amended; and

2.The information contained in the Report fairly presents, in all materialrespects, the financial condition

and results of operations of the Company.

Date: August 9, 2023By:/s/ Mei Mei Hu

Mei Mei Hu

President and Chief Executive Officer

(Principal Executive Officer)

Date: August 9, 2023By:/s/ Jason Pesile

Jason Pesile

Senior Vice President, Finance and Accounting

(Principal Financial and Accounting Officer)